Hepatitis C

Single dose cure for Hepatitis C


Hepatitis C virus (HCV) infects over 170 million people worldwide, and is the main cause of cirrhosis, hepatocellular carcinoma and liver transplant.  There are 7 HCV genotypes, and genotype 1 accounts for 75% of cases. The virus persists in the liver of 85% of those infected and, prior to July 2011, the Standard of Care (SoC) for genotype 1 was pegylated-interferon (PEG-interferon) and ribavirin administered over 48 weeks. The SoC had a cure rate of 50-55% yet was associated with significant side effects including hematological, flu-like symptoms, and cognitive impairment.

Since July 2011, cure rates of up to 75% have been achieved by combining Specifically Targeted Antiviral Therapy (STAT-C) with PEG-interferon and ribavirin, also administered over long periods. However, a significant percentage of patients has either withdrawn due to side effects, or not responded.


Tacere has designed a ddRNAi –based multi-cassette vector called TT-034 which targets 3 parts of the HCV genome in a single intravenous dose. TT-034 has achieved over 90% transfection of liver cells and, by targeting 3 separate, well-conserved regions of HCV simultaneously, it prevents generation of drug-resistant mutants, a major problem in the treatment of Hepatitis C. The targeted regions of HCV are also conserved across all genotypes, so TT-034 has likely application to all HCV-caused conditions. Read more about TT-034 here.


TT-034 has entered a Phase l/lla human clinical trial.

  • The first patient was dosed on May 29, 2014
  • Trial data is being monitored by the independent Data Safety Monitoring Board (DSMB)
  • On July 21, 2014 the DSMB recommended that the study can continue without modification.


  1. Safe, Long-term Hepatic Expression of Anti-HCV shRNA in a Nonhuman Primate Model
    Suhy DA, Kao SC, Mao T, Whiteley L, Denise H, Souberbielle B, Burdick AD, Hayes K, Wright JF, Lavender H, Roelvink P, Kolykhalov A, Brady K, Moschos SA, Hauck B, Zelenaia O, Zhou S, Scribner C, High KA, Renison SH, Corbau R.
    Mol Ther. 2012 Sep;20(9):1737-49. Epub 2012 Jun 26.
    Read abstract. Download PDF
  2. In vitro characterization of the activity of PF-05095808 a novel biological agent for Hepatitis C Virus therapy.
    Lavender H, Brady K, Burden F, Delpuech-Adams O, Denise H. Palmer A, Hannah Perkins H, Savic B, Scott S, Smith-Burchnell C,Troke P, Wright JF, Suhy D, Corbau R.
    Antimicrob Agents Chemother. 2012 Mar; 56(3):1364-75.
    Read abstract. Download PDF




Tacere Therapeutics Inc, 3942 Trust Way, Hayward, CA 94545, USAP. +1 925 858 9299           E. info@tacerebio.com

Copyright © Tacere Therapeutics Ltd. All rights reserved.                   Home | Contact